MyoKardia Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
40.12 M |
Public Float |
25.85 M |
MyoKardia Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.2 |
Market Cap |
$2.27 B |
Shares Outstanding |
46.07 M |
Public Float |
37.89 M |
Address |
333 Allerton Avenue San Francisco California 94080 United States |
Employees | - |
Website | http://www.myokardia.com |
Updated | 07/08/2019 |
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. |